cmi_logo.png
[Latest] Global Life Reinsurance Market Size/Share Worth USD 735.6 Billion by 2033 at a 12.7% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
July 01, 2024 03:30 ET | Custom Market Insights
Austin, TX, USA, July 01, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Life Reinsurance Market Size, Trends and Insights By Type (Facultative...
Hampton Creek Press (print and distribution provided by Simon & Schuster) Announces Behind a Closed Door, the Latest Novel by Writer J.D. Barker
April 17, 2024 13:51 ET | Hampton Creek Press
The long-awaited thriller from New York Times bestselling author J.D. Barker is available for preorder now and will be released on May 13, 2024.
Atyr_Logo.png
aTyr Pharma to Participate in April Investor Conferences
April 01, 2024 08:00 ET | aTyr Pharma, Inc.
aTyr Pharma to Participate in April Investor Conferences
Atyr_Logo.png
aTyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell Diversity
January 29, 2024 08:00 ET | aTyr Pharma, Inc.
aTyr Pharma to present posters on the importance of Neuropilin-2 in immune regulation at the Keystone Symposia on Myeloid Cell Diversity.
Atyr_Logo.png
aTyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023
November 13, 2023 08:00 ET | aTyr Pharma, Inc.
SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its...
Atyr_Logo.png
aTyr Pharma Announces Third Quarter 2023 Results and Provides Corporate Update
November 09, 2023 16:00 ET | aTyr Pharma, Inc.
Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected to complete enrollment early in the second quarter of 2024. Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD initiated...
Atyr_Logo.png
aTyr Pharma Presents Efzofitimod Data Demonstrating Statistically Significant Improvements in Time to Relapse, FVC and Patient Reported Outcomes
September 11, 2023 08:00 ET | aTyr Pharma, Inc.
Post-hoc analysis from Phase 1b/2a study in pulmonary sarcoidosis presented at the European Respiratory Society (ERS) International Congress 2023. 7.7% of patients in the 3.0 and 5.0 mg/kg...
Klang-Lgog-ryb-rgb50.png
“The Life Cycle” Podcast from Klang Games Clarifies the Most Important Questions About the Future of Mankind
April 06, 2023 09:30 ET | Klang Games
BERLIN, April 06, 2023 (GLOBE NEWSWIRE) -- Klang Games, the makers behind the sandbox simulation MMO game SEED, are not only concerned with the future of mankind and the colonization of exoplanets...
Atyr_Logo.png
aTyr Pharma and Foundation for Sarcoidosis Research Announce Town Hall Virtual Meeting on Sarcoidosis and Transitioning from Steroids to New and Investigational Therapies
March 20, 2023 08:00 ET | aTyr Pharma, Inc.
SAN DIEGO, March 20, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of first-in-class medicines from its...
Atyr_Logo.png
aTyr Pharma Announces Fourth Quarter and Full Year 2022 Results and Provides Corporate Update
March 09, 2023 16:00 ET | aTyr Pharma, Inc.
 Phase 3 EFZO-FIT™ study of efzofitimod in patients with pulmonary sarcoidosis enrolling in the U.S., Europe and Japan. Phase 2 proof-of-concept study of efzofitimod in patients with SSc-ILD expected...